 Sclerotherapy esophageal varices thrombogenic cocktail short- long-term efficacy thrombogenic sclerosant tetradecyl sulfate thrombin cefazolin patients majority patients alcoholic cirrhosis Child classification Bleeding cent patients first sclerotherapy In-hospital early weeks mortality cent cent strong correlation hospital mortality severity hepatic disease Long-term follow-up patients mean months survival compliance follow-up sclerotherapy abstention alcohol intake Mortality patients compliant follow-up cent cent patients compliant follow-up sclerotherapy mortality alcoholic cirrhotic patients alcoholic intake cent cent alcohol systemic thrombotic allergic events use bovine thrombin total sclerotherapy sessions